Mycobacterium marinum infection complicated by anti-tumour necrosis factor therapy

References

1. Boulman, N., Rozenbaum, M., Slobodin, G. & Rosner, I. ( 2006; ). Mycobacterium fortuitum infection complicating infliximab therapy in rheumatoid arthritis. Clin Exp Rheumatol 24, 723
   [Google Scholar]
2. Chopra, N., Kirschenbaum, A. E. & Widman, D. ( 2002; ). Mycobacterium marinum tenosynovitis in a patient on etanercept therapy for rheumatoid arthritis. J Clin Rheumatol 8, 265–268.[CrossRef]
   [Google Scholar]
3. Danko, J. R., Gilliland, W. R., Miller, R. S. & Decker, C. F. ( 2009; ). Disseminated Mycobacterium marinum infection in a patient with rheumatoid arthritis receiving infliximab therapy. Scand J Infect Dis 41, 252–255.[CrossRef]
   [Google Scholar]
4. Dare, J. A., Jahan, S., Hiatt, K. & Torralba, K. D. ( 2009; ). Reintroduction of etanercept during treatment of cutaneous Mycobacterium marinum infection in a patient with ankylosing spondylitis. Arthritis Rheum 61, 583–586.[CrossRef]
   [Google Scholar]
5. Díaz, F., Urkijo, J. C., Mendoza, F., de la Viuda, J. M., Blanco, M., Unzurrunzaga, A. & Ayarza, R. ( 2008; ). Mycobacterium chelonae infection associated with adalimumab therapy. Scand J Rheumatol 37, 159–160.[CrossRef]
   [Google Scholar]
6. Ehlers, S. ( 2005; ). Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 41, S199–S203.[CrossRef]
   [Google Scholar]
7. Fallon, J. C., Patchett, S., Gulmann, C. & Murphy, G. M. ( 2008; ). Mycobacterium marinum infection complicating Crohn's disease, treated with infliximab. Clin Exp Dermatol 33, 43–45.
   [Google Scholar]
8. Griffith, D. E., Aksamit, T., Brown-Elliott, B. A., Catanzaro, A, Daley, C., Gordin, F., Holland, S. M., Horsburgh, R., Huitt, G. & other authors ( 2007; ). An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175, 367–416.[CrossRef]
   [Google Scholar]
9. Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N. & Braun, M. M. ( 2001; ). Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345, 1098–1104.[CrossRef]
   [Google Scholar]
10. Malkin, J., Shrimpton, A., Wiselka, M., Barer, M. R., Duddridge, M. & Perera, N. ( 2009; ). Olecranon bursitis secondary to Mycobacterium kansasii infection in a patient receiving infliximab for Behcet's disease. J Med Microbiol 58, 371–373.[CrossRef]
    [Google Scholar]
11. Marie, I., Heliot, P., Roussel, F., Hervé, F., Muir, J. F. & Levesque, H. ( 2005; ). Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab. Rheumatology 44, 1201–1202.[CrossRef]
    [Google Scholar]
12. Martín-Aspas, A., Guerrero-Sánchez, F., García-Martos, P., González-Moya, E., Medina-Varo, F. & Girón González, J. A. ( 2008; ). Bilateral pneumonia by Mycobacterium aurum in a patient receiving infliximab therapy. J Infect 57, 167–169.[CrossRef]
    [Google Scholar]
13. Mufti, A. H., Toye, B. W., Mckendry, R. R. & Angel, J. B. ( 2005; ). Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use. Diagn Microbiol Infect Dis 53, 233–238.[CrossRef]
    [Google Scholar]
14. Pandian, T. K., Deziel, P. J., Otley, C. C., Eid, A. J. & Razonable, R. R. ( 2008; ). Mycobacterium marinum infections in transplant recipients: case report and review of the literature. Transpl Infect Dis 10, 358–363.[CrossRef]
    [Google Scholar]
15. Piersimoni, C. & Scarparo, C. ( 2009; ). Extrapulmonary infections associated with nontuberculous mycobacteria in immunocompetent persons. Emerg Infect Dis 15, 1351–1358.[CrossRef]
    [Google Scholar]
16. Rallis, E., Koumantaki-Mathioudaki, E., Frangoulis, E., Chatziolou, E. & Katsambas, A. ( 2007; ). Severe sporotrichoid fish tank granuloma following infliximab therapy. Am J Clin Dermatol 8, 385–388.[CrossRef]
    [Google Scholar]
17. Salvana, E. M., Cooper, G. S. & Salata, R. A. ( 2007; ). Mycobacterium other than tuberculosis (MOTT) infection: an emerging disease in infliximab-treated patients. J Infect 55, 484–487.[CrossRef]
    [Google Scholar]
18. Shehan, J. M. & Sarma, D. P. ( 2008; ). Mycobacterium mucogenicum: report of a skin infection associated with etanercept. Dermatol Online J 14, 5
    [Google Scholar]
19. Streit, M., Böhlen, L. M., Hunziker, T., Zimmerli, S., Tscharner, G. G., Nievergelt, H., Bodmer, T. & Braathen, L. R. ( 2006; ). Disseminated Mycobacterium marinum infection with extensive cutaneous eruption and bacteremia in an immunocompromised patient. Eur J Dermatol 16, 79–83.
    [Google Scholar]
20. Swart, R. M., van Ingen, J., van Soolingen, D., Slingerland, R., Hendriks, W. D. & den Hollander, J. G. ( 2009; ). Nontuberculous mycobacteria infection and tumor necrosis factor-alpha antagonists. Emerg Infect Dis 15, 1700–1701.[CrossRef]
    [Google Scholar]
21. van Ingen, J., Boeree, M., Janssen, M., Ullmann, E., de Lange, W., de Haas, P., Dekhuijzen, R. & van Soolingen, D. ( 2007; ). Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy. Nat Clin Pract Rheumatol 3, 414–419.
    [Google Scholar]
22. Wallis, R. S., Broder, M. S., Wong, J. & Beenhouwer, D. ( 2004; ). Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 39, 1254–1255.[CrossRef]
    [Google Scholar]
23. Winthrop, K. L., Chang, E., Yamashita, S., Iademarco, M. F. & LoBue, P. A. ( 2009; ). Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis 15, 1556–1561.[CrossRef]
    [Google Scholar]
24. Yim, K., Nazeer, S. H., Kiska, D., Rose, F. B., Brown, D. & Cynamon, M. H. ( 2004; ). Recurrent Mycobacterium xenopi infection in a patient with rheumatoid artritis receiving etanercept. Scand J Infect Dis 36, 150–154.[CrossRef]
    [Google Scholar]